Mighty Therapeutics Announces First Patient Dosed in Phase 4 Confirmatory Study of Elamipretide in Barth Syndrome Press Release / July 8, 2026
Mighty Therapeutics, Formerly Stealth BioTherapeutics, Announces New Name Honoring the Mitochondrial Disease Community Press Release / June 16, 2026June 25, 2026
Stealth Biotheraputics to Present Updates on Elamipretide in Barth Syndrome and POLG Disease at Euromit 2026 Press Release / May 26, 2026June 25, 2026
Stealth BioTherapeutics Provides Commercial Launch Update and Pipeline Progress Across Mitochondrial Disease Portfolio Press Release / April 30, 2026June 25, 2026
Stealth BioTherapeutics to Present Clinical Data for Bevemipretide Eye Drops at the Association for Research in Vision and Ophthalmology 2026 Annual Meeting Press Release / April 27, 2026June 25, 2026
Stealth BioTherapeutics Appoints David A. Brown, Ph.D., as Chief Scientific Officer to Advance the Company’s Pioneering Work in Mitochondrial Medicine Press Release / April 8, 2026June 25, 2026
Stealth BioTherapeutics Announces MRC Business Engagement Fund Grant to Advance Mitochondrial Disease Research Press Release / March 23, 2026June 25, 2026
Stealth BioTherapeutics Provides Commercial and R&D Pipeline Update and Outlines 2026 Strategic Priorities Press Release / January 6, 2026June 25, 2026
